Triggering receptor expressed on myeloid cells-1 (TREM-1) inhibition in atherosclerosis

Pharmacol Ther. 2022 Oct:238:108182. doi: 10.1016/j.pharmthera.2022.108182. Epub 2022 Apr 4.

Abstract

Triggering receptor expressed on myeloid cells-1 (TREM-1) is a transmembrane protein expressed on endothelial cells, white blood cells, smooth muscle cells and platelets. TREM-1 plays an important role in innate immunity. TREM-1 activation pathways are implicated both in sepsis and in non-infectious inflammatory conditions, including atherosclerosis. TREM-1 enhances the subendothelial lipid accumulation and expression of pro-inflammatory cytokines and matrix-degrading enzymes, thereby promoting inflammation and plaque destabilization. TREM-1 inhibitors attenuate the inflammatory process in the atherosclerotic plaque, leading to plaque stabilization. This review focuses on the role of TREM-1 in the pathophysiology of atherosclerosis and the effects of TREM-1 inhibition in the natural history of the disease.

Keywords: Atherosclerosis; Inflammation; Inhibitors; TREM-1.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / metabolism
  • Cytokines / metabolism
  • Endothelial Cells / metabolism
  • Humans
  • Lipids
  • Plaque, Atherosclerotic* / metabolism
  • Triggering Receptor Expressed on Myeloid Cells-1 / metabolism

Substances

  • Cytokines
  • Lipids
  • TREM1 protein, human
  • Triggering Receptor Expressed on Myeloid Cells-1